Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Invir.IO

    Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

    Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

    Published 26 May 2023
    Categorized as 2023, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050, TG6002

    Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors

    Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001

    Published 25 May 2023
    Categorized as 2023, BT-001, BT-001 (EN), dates, dates, Invir.IO, Press release, TG6002

    Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer

    First patient dosed in Phase I trial evaluating TG6050 15

    Published 10 May 2023
    Categorized as 2023, dates, dates, Invir.IO, Press release, TG6050-en, TG6002

    Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

    H. Le et al.AACR 2023Download the poster herePoster Presentation

    Published 19 April 2023
    Categorized as 2023, Invir.IO, Publication

    PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

    P Erbs et al.AACR 2023Download the poster herePoster Presentation

    Published 19 April 2023
    Categorized as 2023, Invir.IO, Publication

    Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators

    JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

    Published 17 April 2023
    Categorized as 2023, Invir.IO, Publication

    TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

    JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

    Published 16 April 2023
    Categorized as 2023, Invir.IO, Publication, publication HP en, TG6050-en

    Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

    Transgene recieves approval to start a Phase I trial of TG6050 15

    Published 6 January 2023
    Categorized as 2023, dates, Invir.IO, Press release, TG6050-en, TG6002

    Transgene announces Financial Calendar for 2023

    Transgene announces Financial Calendar for 2023 15

    Published 4 January 2023
    Categorized as 2023, dates, dates, Invir.IO, Press release, TG6002

    R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

    TRANSGENE R&D DAY

    Published 27 September 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

    Posts navigation

    Page 1 … Page 6 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2023 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo